Mina Madan, MD, MPH

Temporal Spectrum of Ischemic Complications with Percutaneous Coronary Intervention: The ESPRIT Experience

08/01/2008

John Ducas , MD;

William S. Sheldon , MD;

Mark A. Tannenbaum , MD;

Jack E. Smith , MD;

Michael M. Kitt , MD;

Ian C. Gilchrist , MD;

James C. Blankenship , MD;

James E. Tcheng , MD;

Warren J. Cantor , MD;

J. Conor O'Shea , MD;

Karen S. Pieper , MS;

Douglas A. Criger , MPH;

Mina Madan , MD, MPH;

Percutaneous coronary intervention (PCI) is an effective treatment for myocardial ischemia in patients with coronary artery disease. More than one million PCI procedures were performed worldwide in 1998.1 A major limitation of percutaneous...

Percutaneous coronary...

08/01/2008

Journal of Invasive Cardiology

Bailout Use of Platelet Glycoprotein IIb/IIIa Inhibition During Coronary Stent Implantation: Observations from the ESPRIT Trial

08/01/2008

James E. Tcheng , MD;

Michael M. Kitt , MD;

David J. Cohen , MD, MPH, MSc;

Robert J. Chisholm , MD, FRCPC;

Henry K. Lui , MD;

Robert L. Feldman , MD;

Robert Green , MD;

Anne S. Hellkamp , PhD;

Warren J. Cantor , MD;

J. Conor O'Shea , MD;

Mina Madan , MD, MPH;

Potent inhibition of platelet aggregation during percutaneous coronary intervention (PCI) using intravenous antagonists of the platelet glycoprotein (GP) IIb/IIIa receptor results in a significant and sustained reduction in the occurrence of...

Potent inhibition of platelet...

08/01/2008

Journal of Invasive Cardiology